Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2017
The 7th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland
Presentation Date(s):- May 5 – 8, 2017
- Total Presentations: 359
-
+
Immunotherapies and targeted therapies in advanced NSCLC
- Type: Proffered Paper session
- Presentations: 6
- Moderators:L. Paz-Ares
- Coordinates: 5/06/2017, 14:45 - 16:15, Room B
-
+
83O - A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A
14:45 - 15:00 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
84O - Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial
15:00 - 15:15 | Author(s): S. Peters
- Abstract
Loading... -
+
2O - Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture
15:15 - 15:30 | Author(s): G. Mazzaschi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 83O, 84O and 2O
15:30 - 15:50 | Author(s): L. Paz-Ares
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
85O_PR - Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer
15:50 - 16:05 | Author(s): C.K. Lee
- Abstract
Loading... -
+
Invited Discussant 85O_PR
16:05 - 16:15 | Author(s): E. Smit
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
SCLC: New insights
- Type: Educational session
- Presentations: 5
- Moderators:N. Reguart
- Coordinates: 5/07/2017, 11:00 - 12:30, Room C
-
+
What is the optimal thoracic radiotherapy in limited stage SCLC?
11:00 - 11:20 | Author(s): C. Faivre-Finn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Can brain control be improved beyond PCI?
11:20 - 11:40 | Author(s): E. Gkika
- Abstract
No abstract available for this presentation
-
+
New therapies, new era?
11:40 - 12:00 | Author(s): N. Reguart
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
What can CDX models teach us?
12:00 - 12:20 | Author(s): C. Dive
- Abstract
No abstract available for this presentation
-
+
Questions and Answers
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
Targeted therapies and immunotherapies
- Type: Poster Discussion session
- Presentations: 10
- Moderators:S. Ekman
- Coordinates: 5/07/2017, 14:45 - 15:45, Room W
-
+
89PD - Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC
14:45 - 14:45 | Author(s): D. Cortinovis
- Abstract
Loading... -
+
90PD - Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data
14:45 - 14:45 | Author(s): R.S. Herbst
- Abstract
Loading... -
+
91PD_PR - Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
14:45 - 14:45 | Author(s): S.I. Rothschild
- Abstract
Loading... -
+
Invited Discussant 89PD, 90PD and 91PD_PR
14:45 - 15:00 | Author(s): S. Ekman
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
15:00 - 15:15
- Abstract
No abstract available for this presentation
-
+
92PD - First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
15:15 - 15:15 | Author(s): M. Schuler
- Abstract
Loading... -
+
93PD - Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
15:15 - 15:15 | Author(s): J. Corral
- Abstract
Loading... -
+
94PD - Adverse events self-reported by patients with advanced non-small cell lung cancer treated with osimertinib or chemotherapy
15:15 - 15:15 | Author(s): M. Sebastian
- Abstract
Loading... -
+
Invited Discussant 92PD, 93PD and 94PD
15:15 - 15:30 | Author(s): N. Reguart
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
15:30 - 15:45
- Abstract
No abstract available for this presentation
